Articles by Adeline Siew, PhD - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Adeline Siew, PhD

Pharmaco-Kinesis Corporation Develops First Nanodrug Combination for Glioma

May 1, 2013

Pharmaco-Kinesis Corporation (PKC) announced that it is developing the first nanodrug combination of Merck's temozolomide and Celgene's thalidomide (in a 50:50 ratio) for the treatment of gliomas and other cancers. PKC will collaborate with the University of California, San Diego's department of nano-engineering at the Moores cancer centre to develop the nanodroplet formulation.

Actemra Receives FDA Approval for Polyarticular Juvenile Idiopathic Arthritis

May 1, 2013

Genentech announced that FDA has approved Actemra (tocilizumab) for the treatment of polyarticular juvenile idiopathic arthritis (PJIA) in children aged two years and older.

Bayer to Acquire Conceptus for US$1.1 Billion

Apr 30, 2013

Bayer announced that it has signed a merger agreement with US-based birth-control specialist Conceptus.

BioOutsource Opens New Facility in Cambridge, Massachusetts

Apr 24, 2013

BioOutsource, a contract testing services provider to the biopharmaceutical industry, has opened a new facility in Cambridge, Massachusetts. The facility marks the company's first North American offices, which were opened in response to increasing demand for the company's bioanalytical and biosafety services, particularly in the field of biologic and biosimilar characterisation.

AstraZeneca Seals Cancer Nanomedicine Deal with BIND Therapeutics

Apr 23, 2013

AstraZeneca and BIND Therapeutics have formed a strategic collaboration to develop and commercialise BIND's Accurin, a targeted and programmable cancer nanomedicine, based on a molecularly targeted kinase inhibitor developed and owned by AstraZeneca.

Astellas and Ambrx Collaborate on Antibody Drug Conjugates for Oncology

Apr 8, 2013

Astellas and Ambrx have entered into a collaboration to discover and develop novel antibody drug conjugates (ADCs) for an undisclosed number of targets in oncology. ADCs enable targeted delivery of drugs to the target tissue.

Teva and Lonza Review Biosimilars Opportunity

Apr 8, 2013

Teva and Lonza have announced that their joint venture will continue to develop, manufacture and market affordable, efficacious and safe biosimilars.

Regeneron Expands and Creates 400 New Jobs in Westchester

Apr 8, 2013

Regeneron, a biopharmaceutical company based in New York, has announced plans to expand its corporate headquarters and laboratories in Westchester. This expansion will create more than 400 new highly skilled jobs and further cement Hudson Valley's reputation as an emerging epicenter for biopharmaceutical growth.

Endo Pharmaceuticals and GVK Biosciences Form Research Collaboration

Jan 30, 2013

Endo Pharmaceuticals and GVK Biosciences (GVK BIO), a CRO based in India, have entered into an agreement to collaborate on the development of small molecules targeting an undisclosed protein. Using its discovery expertise, GVK BIO will deliver a clinical candidate and Endo will be responsible for the development and commercialization of the product.

ADVERTISEMENT

ADVERTISEMENT

Click here